Home » Stocks » JNJ

Johnson & Johnson (JNJ)

Stock Price: $172.20 USD 0.02 (0.01%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
Market Cap 453.47B
Revenue (ttm) 89.19B
Net Income (ttm) 17.77B
Shares Out 2.63B
EPS (ttm) 6.65
PE Ratio 25.89
Forward PE 17.89
Dividend $4.09
Dividend Yield 2.38%
Trading Day July 30
Last Price $172.20
Previous Close $172.18
Change ($) 0.02
Change (%) 0.01%
Day's Open 172.54
Day's Range 171.84 - 172.98
Day's Volume 5,346,738
52-Week Range 131.09 - 173.38


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.

Other stocks mentioned: FXH, IEIH, IHE, MRNA, PFE, PJP, PPH
13 hours ago - Zacks Investment Research

The healthcare giant has weathered much bigger storms in the past.

16 hours ago - The Motley Fool

A House Oversight subcommittee sent a letter to Johnson & Johnson's (NYSE: JNJ) CEO Alex Gorsky asking for documents and information on any company plans to place a subsidiary into bankruptcy over talc ...

1 day ago - Benzinga

WASHINGTON, July 29, 2021 /PRNewswire/ -- More than 30,000 women cancer victims would retain their constitutional right to have juries decide if talc in Johnson & Johnson's (NYSE:JNJ) baby products caus...

1 day ago - PRNewsWire

Investors should consider more than just the healthcare giant's impressive financial numbers when deciding whether to invest in its stock over the long term.

1 day ago - The Motley Fool

You shouldn't invest your life savings into any one stock, but these three have some serious potential.

Other stocks mentioned: ABT, BDX
1 day ago - The Motley Fool

Shareholders bored by lagging returns might get some excitement in the near future.

1 day ago - The Motley Fool

The extension will give health workers six additional weeks to administer millions of doses of the single-shot vaccine.

1 day ago - Forbes

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?

2 days ago - Zacks Investment Research

The S&P 500 recently notched all-time highs. Well-defined risk/reward setups suggest that these mega caps will be the focus of the next leg higher.

Other stocks mentioned: MGC, PG, SPY
2 days ago - Investopedia

A Black women's advocacy group filed a lawsuit Tuesday accusing Johnson & Johnson of selectively marketing the company's talcum-based products, including Johnson's Baby Powder, to African-American women...

2 days ago - CNN Business

NEW BRUNSWICK, N.J., July 27, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Virtual Wells Fargo Healthcare Conference on Friday, September 10 th.

3 days ago - PRNewsWire

In the face of a comprehensive global tax agreement intended to inhibit tax avoidance opportunities, industry executives and lobbyists are mounting a quiet campaign to push back against the measure, the...

Other stocks mentioned: PFE
3 days ago - Benzinga

What healthcare executives are saying so far about the impact of the coronavirus variant on their businesses is reassuring.

Other stocks mentioned: ABT, ISRG
3 days ago - The Motley Fool

J&J Snack Foods (JJSF) delivered earnings and revenue surprises of 91.14% and 3.57%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Other stocks mentioned: JJSF
4 days ago - Zacks Investment Research

The price action has tested resistance, while the option activity suggests that traders continue to both buy calls and sell puts.

4 days ago - Investopedia

If profit taking leads to further market declines, then investors may want to brace for further volatility with dividend stocks. The post 3 Blue-Chip Dividend Stocks for a Bear Market appeared first on ...

Other stocks mentioned: MCD, WMT
4 days ago - InvestorPlace

These investments will spare you pain during the next market crash.

Other stocks mentioned: BAC, IIPR
5 days ago - The Motley Fool

Johnson & Johnson (NYSE: JNJ) shares have advanced almost 5% since the beginning of July 2021; the company reported better than expected second-quarter results this Wednesday and expects even better tre...

6 days ago - Invezz

Financials, basic materials, energy sectors are stocks Neuberger Berman's Salzmann recommends

YouTube video

Eli Salzmann, portfolio manager of The Neuberger Berman Large Cap Value Fund, joins 'The Exchange' to discuss the future of the market with Kelly Evans. He values traditional financial and energy stocks...

Other stocks mentioned: AON, CMA, GE, JPM, TFC, XOM
1 week ago - CNBC Television

Peak growth may be behind us, says Schroders' Ron Insana

YouTube video

Ron Insana, Schroders senior advisor, and Stephanie Link, HighTower chief investment strategist and portfolio manager, joins 'Power Lunch' to discuss the state of the market and their earnings expectati...

Other stocks mentioned: AAPL, AMD, CAT, CVX, GOOG, GOOGL
1 week ago - CNBC Television

It was a jarring start to the week for Wall Street, with stocks in a seeming freefall as a rise in global Covid-19 cases, specifically the delta variant, had many wondering if the smooth economic recove...

Other stocks mentioned: AXP, IBM, MCD, MRNA, SNAP
1 week ago - Schaeffers Research

On Monday, July 26, J&J Snack Foods (NASDAQ:JJSF) will release its latest earnings report. Decipher the announcement with Benzinga's help.

Other stocks mentioned: JJSF
1 week ago - Benzinga

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified Netflix among others.

Other stocks mentioned: CMG, IBM, INTC, NFLX
1 week ago - Forbes

J&J's smaller partner could benefit in a big way from the approval of a new version of blood cancer drug Darzalex.

1 week ago - The Motley Fool

Moderna, Pfizer, and Johnson & Johnson are optimistic.

Other stocks mentioned: MRNA, PFE
1 week ago - The Motley Fool

Guillain-Barre syndrome (GBS) will be listed as a very rare side effect of Johnson & Johnson's (NYSE: JNJ) COVID-19 Vaccine. The warning will be included in the product information to raise awareness am...

1 week ago - Benzinga

The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.

Other stocks mentioned: ABBV, AMGN, BMY, FHLC, GILD, IYH, MRK ...
1 week ago - Zacks Investment Research

Examining key financial figures can help you pick companies that are likely to keep distributing those steady payments.

Other stocks mentioned: CL, T
1 week ago - The Motley Fool

The company recorded 164 million in COVID-19 vaccine sales in the second quarter, up 64% from the first, and aims to fetch $2.5 billion in sales by the end of the year.

1 week ago - Zacks Investment Research

Attorney generals of several states reach settlement deal with J&J (JNJ) and three drug distributors - MCK, CAH and ABC - related to thousands of opioid abuse litigations. Non-participating states may j...

Other stocks mentioned: ABC, CAH, MCK
1 week ago - Zacks Investment Research

Coronavirus variants will be the key variable.

Other stocks mentioned: BNTX, MRNA, PFE
1 week ago - The Motley Fool

It shouldn't impact the healthcare giant very much.

1 week ago - The Motley Fool

States reach deal to settle with opioid distributors, Johnson & Johnson

YouTube video

CNBC's Meg Tirrell joins Shep Smith to report on a $26 billion settlement between states and opioid distributors, as well as Johnson & Johnson. Not all states have agreed to accept the settlement.

1 week ago - CNBC Television

States announce $26 billion settlement to resolve opioid lawsuits: RPT

YouTube video

Chris Meekins, Healthcare Policy Research Analyst at Raymond James, joins Yahoo Finance's Kristin Myers and Alexis Christoforous to discuss healthcare talks in Washington this week and the latest news o...

Other stocks mentioned: ABC, CAH, MCK
1 week ago - Yahoo Finance

A group of state attorneys general unveiled on Wednesday a landmark, $26 billion settlement resolving claims that the three largest US drug distributors and drugmaker Johnson & Johnson helped fuel a dea...

1 week ago - New York Post

Square, Johnson & Johnson, Coca-Cola and Chipotle Mexican Grill were our top stock trades for Thursday. Now, let's look at the charts.

Other stocks mentioned: KO, SQ, CMG
1 week ago - InvestorPlace

Fauci: Vaccines are safe and effective against delta variant

YouTube video

"We just need to get more and more people vaccinated," Dr. Anthony Fauci, chief medical advisor to President Biden, tells 'Closing Bell.' He emphasizes the need for data-based conclusions, like the fact...

Other stocks mentioned: BNTX, MRNA, PFE
1 week ago - CNBC Television

What did the stock market do today? It began to address the opioid crisis, it tuned in on Bitcoin and it saw a devastating Olympics loss.

Other stocks mentioned: ABC, MCK
1 week ago - InvestorPlace

A group of states Attorneys General announced a proposed $26 billion global settlement Wednesday that, if approved, will resolve claims against the "big three" drug distributors — McKesson Corporation, ...

1 week ago - CNN Business

J&J Shot Found to Raise Fewer Antibodies Against Delta Variant

YouTube video

Jul.21 -- Johns Hopkins Bloomberg School of Public Health Professor and Virologist Andrew Pekosz discusses the efficacy of the Johnson & Johnson Covid-19 vaccine against the delta variant. The Bloomberg...

1 week ago - Bloomberg Markets and Finance

The deal will resolve thousands of opioid crisis-related lawsuits.

1 week ago - Forbes

States reach $26B settlement with opioid distributors and Johnson & Johnson

YouTube video

CNBC's Meg Tirrell reports on a settlement in a lawsuit against opioid distributors in the U.S.

1 week ago - CNBC Television

Study shows Johnson & Johnson vaccine may be less effective against Delta variant

YouTube video

#Johnson&Johnson Dr. Amesh Adalja, Senior scholar Johns Hopkins center for health security, joins Yahoo Finance's Kristin Myers to discuss the latest on the coronavirus pandemic, vaccines and the Delta ...

1 week ago - Yahoo Finance

As the Delta variant rapidly spreads across the U.S., accounting for 83% of the country's cases, a new study showed that neutralizing titers induced by Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine d...

1 week ago - Benzinga

Shares of Johnson & Johnson ( JNJ , Financial), one of Yacktman Asset Management (Trades, Portfolio)'s top 10 holdings, rose slightly above the flatline on Wednesday after reporting second-quarter earni...

1 week ago - GuruFocus

J&J CFO: Not-for-Profit Vaccine Price Likely to End in 2021

YouTube video

Jul.21 -- Johnson & Johnson CFO Joseph Wolk discusses the efficacy of the company's Covid-19 vaccine against the delta variant, second-quarter results, and efforts to address damage claims over its talc...

1 week ago - Bloomberg Markets and Finance

Today's pre-market trading activity appears to have reverted back to the sector rotation between growth/tech names and cyclical/value stocks.

Other stocks mentioned: VZ, VZA
1 week ago - Zacks Investment Research

Johnson & Johnson posted strong second-quarter results on Tuesday (July 21), beating Wall Street estimates as sales of beauty and skincare products begin to recover from COVID-19 and patients resume pre...

1 week ago - PYMNTS

About JNJ

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the S... [Read more...]

Drug Manufacturers-General
Alex Gorsky
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2020, JNJ's revenue was $82.58 billion, an increase of 0.64% compared to the previous year's $82.06 billion. Earnings were $14.71 billion, a decrease of -2.68%.

Financial Statements

Analyst Forecasts

According to 19 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is 187.39, which is an increase of 8.82% from the latest price.

Price Target
(8.82% upside)
Analyst Consensus: Buy